Clinically, intravenous iron administration or SGLT2 inhibition with empagliflozin improves mitochondrial energy metabolism, enhances iron utilization and erythropoiesis, and subsequently improves cardiac and skeletal muscle function, leading to enhanced exercise capacity and left ventricular performance in HF patients (42–45). This evidence concerns the gene SLC5A2 and hydrops fetalis.